Vimta Labs Limited (VIMTALABS.NS)
INR 1016.0
(2.42%)
INR 1016.0
(2.42%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -66 Million INR | 57.45% |
| 2022 | -155.12 Million INR | -281.62% |
| 2021 | 85.41 Million INR | -64.74% |
| 2020 | 242.22 Million INR | -12.72% |
| 2019 | 277.52 Million INR | 19.83% |
| 2018 | 231.59 Million INR | -38.99% |
| 2017 | 379.6 Million INR | -10.74% |
| 2016 | 425.26 Million INR | 86.6% |
| 2015 | 227.89 Million INR | 755.01% |
| 2014 | 26.65 Million INR | -4.46% |
| 2013 | 27.89 Million INR | -71.89% |
| 2012 | 99.24 Million INR | -49.23% |
| 2011 | 195.47 Million INR | -18.09% |
| 2010 | 238.63 Million INR | -4.67% |
| 2009 | 250.32 Million INR | 7.5% |
| 2008 | 232.85 Million INR | -7.48% |
| 2007 | 251.67 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 251.58 Million INR | 481.18% |
| 2023 Q1 | 391.45 Million INR | 352.36% |
| 2023 Q4 | -66 Million INR | -125.22% |
| 2023 Q2 | 4.05 Million INR | -98.97% |
| 2023 Q3 | 261.68 Million INR | 6361.23% |
| 2023 FY | -66 Million INR | 57.45% |
| 2022 FY | -155.12 Million INR | -281.62% |
| 2022 Q1 | 108 Million INR | 26.45% |
| 2022 Q2 | -82.97 Million INR | -176.82% |
| 2022 Q4 | -155.12 Million INR | -158.59% |
| 2022 Q3 | 264.74 Million INR | 419.08% |
| 2021 Q2 | 221.38 Million INR | 236.19% |
| 2021 FY | 85.41 Million INR | -64.74% |
| 2021 Q4 | 85.41 Million INR | 80.0% |
| 2021 Q3 | 47.44 Million INR | -78.57% |
| 2021 Q1 | 65.85 Million INR | -72.81% |
| 2020 FY | 242.22 Million INR | -12.72% |
| 2020 Q1 | 66.74 Million INR | -75.95% |
| 2020 Q4 | 242.22 Million INR | 337.38% |
| 2020 Q3 | 55.38 Million INR | -46.88% |
| 2020 Q2 | 104.26 Million INR | 56.22% |
| 2019 Q2 | 195.87 Million INR | 634.42% |
| 2019 Q1 | 26.67 Million INR | -88.48% |
| 2019 FY | 277.52 Million INR | 19.83% |
| 2019 Q4 | 277.52 Million INR | 1110.29% |
| 2019 Q3 | 22.93 Million INR | -88.29% |
| 2018 Q2 | 271.07 Million INR | 1258.75% |
| 2018 FY | 231.59 Million INR | -38.99% |
| 2018 Q3 | 27.53 Million INR | -89.84% |
| 2018 Q1 | 19.95 Million INR | -94.74% |
| 2018 Q4 | 231.59 Million INR | 741.23% |
| 2017 Q2 | 362.36 Million INR | 2784.92% |
| 2017 FY | 379.6 Million INR | -10.74% |
| 2017 Q4 | 379.6 Million INR | 2203.4% |
| 2017 Q3 | 16.48 Million INR | -95.45% |
| 2017 Q1 | 12.56 Million INR | -97.05% |
| 2016 Q4 | 425.26 Million INR | 1213.96% |
| 2016 Q1 | 34.7 Million INR | -84.77% |
| 2016 FY | 425.26 Million INR | 86.6% |
| 2016 Q2 | 302.19 Million INR | 770.66% |
| 2016 Q3 | 32.36 Million INR | -89.29% |
| 2015 Q3 | 16.11 Million INR | -64.43% |
| 2015 FY | 227.89 Million INR | 755.01% |
| 2015 Q4 | 227.89 Million INR | 1314.37% |
| 2015 Q2 | 45.3 Million INR | 343.11% |
| 2015 Q1 | 10.22 Million INR | -61.64% |
| 2014 Q4 | 26.65 Million INR | 78.69% |
| 2014 Q1 | 39.09 Million INR | 40.12% |
| 2014 Q3 | 14.91 Million INR | -36.84% |
| 2014 Q2 | 23.61 Million INR | -39.58% |
| 2014 FY | 26.65 Million INR | -4.46% |
| 2013 Q1 | 18.47 Million INR | -81.38% |
| 2013 FY | 27.89 Million INR | -71.89% |
| 2013 Q2 | 66.47 Million INR | 259.75% |
| 2013 Q4 | 27.89 Million INR | 95.64% |
| 2013 Q3 | 14.26 Million INR | -78.55% |
| 2012 Q4 | 99.24 Million INR | 0.0% |
| 2012 Q2 | 107.34 Million INR | 0.0% |
| 2012 FY | 99.24 Million INR | -49.23% |
| 2011 FY | 195.47 Million INR | -18.09% |
| 2011 Q4 | 195.47 Million INR | 0.0% |
| 2010 FY | 238.63 Million INR | -4.67% |
| 2009 FY | 250.32 Million INR | 7.5% |
| 2008 FY | 232.85 Million INR | -7.48% |
| 2007 FY | 251.67 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Krsnaa Diagnostics Limited | 1.06 Billion INR | 106.212% |
| Dr. Lal PathLabs Limited | -5.83 Billion INR | 98.869% |
| Metropolis Healthcare Limited | 1.25 Billion INR | 105.244% |
| Thyrocare Technologies Limited | 24.5 Million INR | 369.388% |
| Vijaya Diagnostic Centre Limited | 1.86 Billion INR | 103.546% |